Abstract: The invention relates to chemically as well as physically stable compositions comprising Factor VII or a Factor VII-related polypeptide such that these compositions can be stored, handled and used at room temperature.
Type:
Grant
Filed:
September 25, 2006
Date of Patent:
October 30, 2012
Assignee:
Novo Nordisk Health Care AG
Inventors:
Michael Bech Jensen, Birthe Lykkegaard Hansen, Troels Kornfelt
Abstract: The present invention provides a cytotoxic 7 to 25 mer peptide with three or more cationic residues which has one or more non-genetic bulky and lipophilic amino acids, as well as esters, amides, salts and cyclic derivatives thereof as well as methods of preparing the peptides, pharmaceutical compositions containing them and their use as medicaments, particularly as antibacterions or antitumoral agents. In a preferred aspect, the invention provides the use of said peptides in a method of inducing adaptive immunity against tumor growth or establishment in a subject, as well as the use of other lytic agents in a method of inducing adaptive immunity in a subject.
Type:
Grant
Filed:
March 21, 2007
Date of Patent:
October 9, 2012
Assignee:
Lytix Biopharma AS
Inventors:
Liv Tone Eliassen, Gerd Berge, Baldur Sveinbjørnsson, John Sigurd Svendsen, Øystein Rekdal
Abstract: The present invention provides peptides consisting of L- and/or D-amino acids and combinations thereof, which affect platelets by action on the collagen receptor, glycoprotein VI (GPVI). More specifically, however, the peptides act on the GPVI-FcR? signaling complex. The invention also provides lipid and sugar conjugated peptides comprising L- or D-amino acids. The invention still further provides a method of designing of the peptides and lipid- and/or sugar-conjugated peptides comprising L- or D-amino acids. The present invention further relates to the therapy of various disease states involving the use of these peptides and compounds. Specifically, the peptides and compounds are useful in the treatment and/or prevention of a disease or condition involving platelet activation and aggregation, and more particularly, collagen-induced platelet activation and aggregation. They also are useful in the production of medical devices comprising peptide matrices (i.e., for example, cardiovascular stents).
Abstract: The present invention relates to a method of regulating mammalian target-of-rapamycin (mTOR) by regulating a phospholipase D (PLD) activity that generates a complex with mTOR. Further, the present invention also relates to a method of screening inhibitors of mTOR, and a method and a composition for treating mTOR-related metabolic diseases by inhibiting mTOR.
Type:
Grant
Filed:
August 3, 2007
Date of Patent:
October 2, 2012
Assignee:
Postech Academy-Industry Foundation
Inventors:
Sung-Ho Ryu, Pann-Ghill Suh, Sang-Hoon Ha, Do-Hyung Kim, Il-Shin Kim, Jung-Hwan Kim, Mi-Nam Lee, Hyun-Ju Lee, Jong Heon Kim, Sung-Key Jang, Tae-Hoon Lee
Abstract: Peptides have been identified that bind with high affinity to hair. Peptide-based hair reagents formed by coupling a hair-binding peptide to a benefit agent are described. The peptide-based hair reagents include peptide-based hair conditioners and hair colorants. The peptide-based hair conditioners and hair colorants are comprised of at least one hair-binding peptide coupled to a hair conditioning agent or a coloring agent, respectively.
Type:
Grant
Filed:
August 26, 2008
Date of Patent:
September 25, 2012
Assignees:
E I du Pont de Nemours and Company
Inventors:
R. Edward Benson, Stephen R. Fahnestock, Paul Hamilton, John P. O'Brien, Hong Wang
Abstract: The invention relates to a process for purifying a protein by mixing a protein preparation with a solution having a first salt and a second salt, wherein each salt has a different lyotropic value, and loading the mixture onto a hydrophobic interaction chromatography column. The dynamic capacity of the column for a protein using the two salt combination will be increased compared with the dynamic capacity of the column for either single salt alone.
Abstract: The present invention concerns a process for the purification of macrolide antibiotics. More specifically it concerns a process for the purification of macrolide antibiotics that result in a white powder. The powder remains white also after some time of storage. The process of the present invention is performed by dissolving the macrolide antibiotics, e.g. commercial vancomycin hydrochloride, in water and subjecting the solution to ultrafiltration with a membrane having nominal retention lower than 30,000 Da, preferably of 10,000 Da. The purified solution is preferably concentrated by reversed osmosis and then lyophilized at the optimized conditions of pressure and temperature to obtain a white powder.
Abstract: Peptides have been identified that bind with high affinity to dyed hair. Peptide-based hair reagents formed by coupling a dyed-hair-binding peptide to a benefit agent are described. The peptide-based hair reagents include peptide-based hair conditioners and hair colorants. The peptide-based hair conditioners and hair colorants are comprised of a dyed-hair-binding peptide coupled to a hair conditioning agent or a coloring agent, respectively. The peptide-based hair reagents or the dyed-hair-binding peptides may also be used as a protective sealant to improve color retention of dyed hair.
Type:
Grant
Filed:
August 26, 2008
Date of Patent:
September 11, 2012
Assignees:
E I du Pont de Nemours and Company
Inventors:
R. Edward Benson, Stephen R. Fahnestock, Paul Hamilton, John P. O'Brien, Hong Wang
Abstract: The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In particular, the present invention relates to 49 novel peptide sequences derived from HLA class II molecules of human tumor cell lines which can be used in vaccine compositions for eliciting anti-tumor immune responses.
Abstract: Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for treatment or prevention of infections caused by such microorganisms. Certain peptides are disclosed utilizing a structure-based rational design relating to an antimicrobial peptide, V681, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face. Also disclosed are peptides with one or more amino acids in the D configuration, including peptides with all amino acids in the D configuration.
Type:
Grant
Filed:
December 15, 2005
Date of Patent:
August 28, 2012
Assignee:
The Regents of the University of Colorado
Inventors:
Robert S. Hodges, Yuxin Chen, Michael Vasil, Robert E. W. Hancock, Susan W. Farmer
Abstract: A controlled release composition containing a physiologically active substance in high content, suppressing the initial excess release, and achieving a stable release speed over a long period of time is provided. A controlled release composition comprising (1) a physiologically active substance or salt thereof in an amount of about 14% (w/w) to about 24% (w/w) based on the total composition weight, (2) hydroxynaphthoic acid selected from the group consisting of 3-hydroxy-2-naphthoic acid and 1-hydroxy-2-naphthoic acid or salt thereof, and (3) a lactic acid polymer or salt thereof having a weight-average molecular weight of 15000 to 50000 in which the content of polymers having molecular weights of 5000 or less is about 5% by weight or less, wherein the molar ratio of said hydroxynaphthoic acid or salt thereof to said physiologically active substance or salt thereof is from 3:4 to 4:3.
Type:
Grant
Filed:
March 16, 2011
Date of Patent:
August 21, 2012
Assignee:
Takeda Pharmaceutical Company Limited
Inventors:
Kazumichi Yamamoto, Akiko Yamada, Yoshio Hata
Abstract: The invention concerns a method for producing an aqueous albumin solution from a starting albumin solution which contains stabilizer molecules which are capable of occupying binding sites of the albumin, wherein in a method for increasing the albumin binding capacity (ABiC) for other molecules, at least a portion of the stabilizer molecules is removed from the albumin of the starting albumin solution and separated from the starting albumin solution.
Abstract: The present invention generally relates to methods and compositions for generating vancomycin analogs. Specifically the invention relates to generating a vancomycin library through chemoselective ligation of a sugar moiety with a vancomycin aglycon. In particular, the present invention provides a library of vancomycin analogs, where the member of the library comprises at least one vancomycin analog selected from 2?-N-acyldecanoyl-glucosyl vancomycin neoglycoside, 3?-N-acyldecanoyl-glucosyl vancomycin neoglycoside, 4?-N-acyldecanoyl-glucosyl vancomycin neoglycoside, 6?-N-acyldecanoyl-glucosyl vancomycin neoglycoside, 2?-N-acylbiphenyl-glucosyl vancomycin neoglycoside, 3?-N-acylbiphenoyl-glucosyl vancomycin neoglycoside, 4?-N-acylbiphenoyl-glucosyl vancomycin neoglycoside and 6?-N-acylbiphenoyl-glucosyl vancomycin neoglycoside.
Abstract: This document provides methods and materials related to treating liver conditions. For example, the methods and materials relating to the use of cAMP inhibitors to treat liver conditions are provided.
Type:
Grant
Filed:
May 1, 2006
Date of Patent:
July 31, 2012
Assignee:
Mayo Foundation for Medical Education and Research
Inventors:
Nicholas F. Larusso, Tetyana V. Masyuk, Melissa Muff-Luett
Abstract: The present invention relates to a method for precipitation of peptide where the mixing step of the peptide with the precipitation aid and the precipitation itself are specially separated.
Abstract: The invention relates to the use of tryptophan-containing, in particular tryptophan- and tyrosine-containing, peptides as antioxidants. The compounds can be used for the therapy or prophylaxis of syndromes and disorders associated with unwanted oxidative processes in the extracellular space.
Type:
Grant
Filed:
December 4, 2000
Date of Patent:
July 31, 2012
Assignee:
Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V.
Abstract: Peptide analogs of nociceptin/orphanin FQ, compositions thereof, and their use in treatment of disorders and dysfunctions related to activation or blocking of NOP receptors are described.
Abstract: Novel fluorinated synthetic analogs of hGH-RH(1-30)NH2 that inhibit the release of growth hormone from the pituitary in mammals as well as inhibit the proliferation of human cancers through a direct effect on the cancer cells, and to therapeutic compositions containing these novel peptides and their use.
Type:
Grant
Filed:
September 17, 2009
Date of Patent:
July 24, 2012
Assignees:
University of Miami, The United States of America as represented by the Department of Veterans Affairs
Inventors:
Andrew Schally, Jozsef Varga, Marta Zarandi, Ren Zhi Cai
Abstract: The present invention relates to a method of producing a whey protein hydrolysate using a microbial endopeptidase which specifically cleaves on the carboxy terminal side of arginine or lysine. The invention also relates to use of such whey protein hydrolysate in sports drinks or in clinical nutrition.
Abstract: Patients needing NO donor therapy or inhibition of pathologically proliferating cells or increased NO bioactivity are treated with a therapeutically effective amount of an inhibitor of glutathione-dependent formaldehyde dehydrogenase.
Type:
Grant
Filed:
September 24, 2009
Date of Patent:
July 10, 2012
Assignee:
Duke University
Inventors:
Jonathan S. Stamler, Limin Liu, Alfred Hausladen, Raphael Nudelman